share_log

Medtronic Shares Are Trading Lower After the Company Announced the Six-month Results From the Full Cohort of the SPYRAL HTN-ON MED Trial. For the Primary Endpoint, RDN Did Not Demonstrate a Statistically Significant Reduction.

Benzinga ·  Nov 8, 2022 08:34
Medtronic shares are trading lower after the company announced the six-month results from the full cohort of the SPYRAL HTN-ON MED trial. For the primary endpoint, RDN did not demonstrate a statistically significant reduction.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment